10.3969/j.issn.1671-5411.2014.02.003 [DOI] [PMC free article] [PubMed] [Google Scholar] Zheng J.-P., Wen F.-Q., Bai C.-X., Wan H.-Y., Kang J., Chen P., et al
PubMed Central, Ganguly, Paul, and Sreyoshi Fatima Alam
I'm just going to give you enough to survive the rest
Benefits (Research Focus) GHRH receptor agonism studied for selective stimulation of the GHRH receptor and pulsatile growth hormone release IGF-1 axis activation investigated for downstream hepatic IGF-1 production and somatotropic signaling Visceral adipose tissue research explored for VAT-specific endpoints in lipodystrophy and metabolic models Lipid metabolism examined for hepatic lipid handling and triglyceride pathway endpoints DPP-IV resistance researched for extended pharmacokinetic profile via trans-3-hexenoic acid N-terminal modification What Researchers Look At Plasma GH and IGF-1 dynamics following GHRH receptor stimulation Visceral adipose tissue (VAT) measurements via CT or MRI in lipodystrophy research models Pulsatile vs sustained GH release patterns and downstream somatotropic endpoints Hepatic steatosis, liver fat fraction, and ALT/AST endpoints Comparative pharmacology versus CJC-1295 (DAC and No DAC variants), sermorelin, and other GHRH analogs Quick Specs Form: Lyophilized white powder Net Peptide Content: 20 mg per vial Quantity: 1 vial Appearance: White to off-white lyophilizate Reconstitution: Bacteriostatic or sterile water (added by the end researcher) Purity: 99% by HPLC Identity: MS-verified (per COA) Storage: Protect from light Identity Basics Compound: Tesamorelin Synonyms: TH9507
Mais la plupart de ces travaux restent au stade prclinique, et aucun traitement na encore t valid pour ces usages
